Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst

2026-06-04 07:18:30 ET

My bullish outlook for Grifols ( GRFS ) stems from an alternative viewpoint regarding the storyline compared to what I believe has been used by the market. The most common view is that Grifols is a highly leveraged European healthcare company that will need to demonstrate the ability to grow, refinance and produce cash flow simultaneously. What is more intriguing about Grifols is that it is transitioning toward becoming a plasma infrastructure company during a time when plasma-derived medicines are viewed as strategic healthcare assets versus typical biologic drugs....

Read the full article on Seeking Alpha

For further details see: